INOVIO PHARMACEUTICALS, INC.
About INOVIO PHARMACEUTICALS, INC.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $65.3K
- Net income
- -$84.9M
- Total assets
- $74.3M
- Market cap
- $88.0M
- Operating margin
- -132871.3%
- Net margin
- -130000.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $65.3K
- Operating expenses
- $86.9M
- Operating income
- -$86.8M
- Income tax
- $0
- Net income
- -$84.9M
- EPS (basic)
- $-1.81
- EPS (diluted)
- $-1.81
Balance sheet
- Total assets
- $74.3M
- Current assets
- $61.1M
- Total liabilities
- $50.2M
- Current liabilities
- $43.7M
- Shareholders’ equity
- $24.1M
Cash flow
- Operating cash flow
- -$88.6M
- Investing cash flow
- $14.0M
- Financing cash flow
- $53.1M
- Net cash flow
- -$21.5M
Statements via Polygon.io (SEC filings)
- Market cap
- $88.0M
- EPS (diluted)
- $-1.81
- Shares outstanding
- 80.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 8, 1998
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $84.9M in FY2025.
- Revenue declined 96% from FY2021 to FY2025.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review INOVIO PHARMACEUTICALS, INC..
Write a review
News about INOVIO PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
